Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Poliomyelitis - Drugs In Development, 2022, provides an overview of the Poliomyelitis (Infectious Disease) pipeline landscape.
Polio is a highly infectious disease caused by a virus. It invades the nervous system, and causes total paralysis in a matter of hours. Symptoms include fever, fatigue, headache, vomiting, stiffness in the neck and pain in the limbs. Preventive measures such as the use of vaccines are effective for polio.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Poliomyelitis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Poliomyelitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Poliomyelitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Poliomyelitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 8, 5, 3, 4 and 5 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 4, 2, 2, 3 and 1 molecules, respectively.
Poliomyelitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Poliomyelitis (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Poliomyelitis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Poliomyelitis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Poliomyelitis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Poliomyelitis (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Poliomyelitis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Poliomyelitis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Poliomyelitis - Overview
Poliomyelitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Poliomyelitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Poliomyelitis - Companies Involved in Therapeutics Development
Beijing Minhai Biotechnology Co Ltd
Beijing Tiantan Biological Products Co Ltd
Bharat Biotech Ltd
Biken Co Ltd
Biological E Ltd
Biological Mimetics Inc
Boryung Pharmaceutical Co Ltd
CanSino Biologics Inc
Grifols SA
Helix Biogen Institute
Intravacc BV
Johnson & Johnson
KM Biologics Co Ltd
LG Chem Ltd
Micron Biomedical Inc
Nanolek
Panacea Biotec Ltd
Serum Institute of India Pvt Ltd
Shantha Biotechnics Pvt Ltd
Statera Biopharma Inc
Vaxxas Inc
Wuhan Institute of Biological Products Co Ltd
Poliomyelitis - Drug Profiles
(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
(diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
(diphtheria + tetanus + pertussis (acellular) + poliomyelitis) vaccine - Drug Profile
Product Description
Mechanism Of Action
(diphtheria + tetanus + pertussis (acellular) + poliomyelitis) vaccine - Drug Profile
Product Description
Mechanism Of Action
(diphtheria + tetanus + pertussis + poliomyelitis + haemophilus influenzae [serotype B]) vaccine - Drug Profile
Product Description
Mechanism Of Action
BK-1310 - Drug Profile
Product Description
Mechanism Of Action
CSB-017 - Drug Profile
Product Description
Mechanism Of Action
immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
JNJ-2348 - Drug Profile
Product Description
Mechanism Of Action
KD-2396 - Drug Profile
Product Description
Mechanism Of Action
KD-370 - Drug Profile
Product Description
Mechanism Of Action
LBVC - Drug Profile
Product Description
Mechanism Of Action
LBVD - Drug Profile
Product Description
Mechanism Of Action
polio (trivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
polio [serotype 1] vaccine - Drug Profile
Product Description
Mechanism Of Action
polio [serotype 2] vaccine - Drug Profile
Product Description
Mechanism Of Action
polio [serotype 2] vaccine 1 - Drug Profile
Product Description
Mechanism Of Action
polio [serotype 3] (monovalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
polio [serotype 3] vaccine - Drug Profile
Product Description
Mechanism Of Action
polio [serotype 3] vaccine - Drug Profile
Product Description
Mechanism Of Action
polio [serotypes 1, 2, 3] vaccine - Drug Profile
Product Description
Mechanism Of Action
polio [strain Sabin] vaccine - Drug Profile
Product Description
Mechanism Of Action
polio [strain Sabin] vaccine - Drug Profile
Product Description
Mechanism Of Action
polio [strain Sabin] vaccine - Drug Profile
Product Description
Mechanism Of Action
polio [strain Sabin] vaccine - Drug Profile
Product Description
Mechanism Of Action
polio vaccine - Drug Profile
Product Description
Mechanism Of Action
polio vaccine - Drug Profile
Product Description
Mechanism Of Action
polio vaccine - Drug Profile
Product Description
Mechanism Of Action
polio vaccine - Drug Profile
Product Description
Mechanism Of Action
polio vaccine - Drug Profile
Product Description
Mechanism Of Action
polio vaccine - Drug Profile
Product Description
Mechanism Of Action
polio vaccine 2 - Drug Profile
Product Description
Mechanism Of Action
poliomyelitis (trivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
poliomyelitis [sabin] (vero cell) vaccine - Drug Profile
Product Description
Mechanism Of Action
poliomyelitis [serotype PV3] (virus like particles) vaccine - Drug Profile
Product Description
Mechanism Of Action
poliomyelitis vaccine - Drug Profile
Product Description
Mechanism Of Action
poliomyelitis vaccine - Drug Profile
Product Description
Mechanism Of Action
poliomyelitis vaccine + rotavirus vaccine - Drug Profile
Product Description
Mechanism Of Action
SA-702 - Drug Profile
Product Description
Mechanism Of Action
Poliomyelitis - Dormant Projects
Poliomyelitis - Discontinued Products
Poliomyelitis - Product Development Milestones
Featured News & Press Releases
Jun 09, 2022: Sinovac Biotech receives WHO prequalification for polio vaccine
Apr 12, 2022: Pertussis, Diphtheria, Tetanus, Polio, Hib vaccine filed in Japan: BIKEN/Mitsubishi
Apr 11, 2022: Notification of manufacturing and marketing approval application for pertussis/diphtheria/tetanus/inactivated polio/Hib combined vaccine (BK1310/MT-2355)
Apr 11, 2022: Marketing authorization application of pertussis, diphtheria, tetanus, inactivated polio and Hib combined vaccine (BK1310/MT-2355)
Jul 20, 2021: Intravacc's inactivated polio vaccine, out licensed to Sinovac, receives market authorization in China
Dec 09, 2020: New polio vaccine against strain that threatens eradication is safe and generates immune response in adults, young children, and infants
Apr 23, 2020: AJ Vaccines secures WHO Prequalification for polio vaccine Picovax
Apr 16, 2019: Sinovac announces positive results from Phase III trial Of a Sabin Strain-Based Inactivated Polio Vaccine (sIPV) published in the journal of Infectiou
Mar 11, 2019: LG Chem gets $33.4 mil. from Gates Foundation for vaccine development
May 21, 2018: A single-injection vaccine for the polio virus
Apr 19, 2018: Sinovac Announces Preliminary Results of Phase III Trial on sIPV
Dec 10, 2015: Sinovac Obtains Clinical Trial Approval for Sabin-IPV Candidate
Sep 16, 2014: Vaxxas initiates research project on advancing next generation technology for polio vaccine delivery
Oct 31, 2012: Statens Serum Institut receives a grant of $158,739 from Bill & Melinda Gates Foundation
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Poliomyelitis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Poliomyelitis - Pipeline by Beijing Minhai Biotechnology Co Ltd, 2022
Poliomyelitis - Pipeline by Beijing Tiantan Biological Products Co Ltd, 2022
Poliomyelitis - Pipeline by Bharat Biotech Ltd, 2022
Poliomyelitis - Pipeline by Biken Co Ltd, 2022
Poliomyelitis - Pipeline by Biological E Ltd, 2022
Poliomyelitis - Pipeline by Biological Mimetics Inc, 2022
Poliomyelitis - Pipeline by Boryung Pharmaceutical Co Ltd, 2022
Poliomyelitis - Pipeline by CanSino Biologics Inc, 2022
Poliomyelitis - Pipeline by Grifols SA, 2022
Poliomyelitis - Pipeline by Helix Biogen Institute, 2022
Poliomyelitis - Pipeline by Intravacc BV, 2022
Poliomyelitis - Pipeline by Johnson & Johnson, 2022
Poliomyelitis - Pipeline by KM Biologics Co Ltd, 2022
Poliomyelitis - Pipeline by LG Chem Ltd, 2022
Poliomyelitis - Pipeline by Micron Biomedical Inc, 2022
Poliomyelitis - Pipeline by Nanolek, 2022
Poliomyelitis - Pipeline by Panacea Biotec Ltd, 2022
Poliomyelitis - Pipeline by Serum Institute of India Pvt Ltd, 2022
Poliomyelitis - Pipeline by Shantha Biotechnics Pvt Ltd, 2022
Poliomyelitis - Pipeline by Statera Biopharma Inc, 2022
Poliomyelitis - Pipeline by Vaxxas Inc, 2022
Poliomyelitis - Pipeline by Wuhan Institute of Biological Products Co Ltd, 2022
Poliomyelitis - Dormant Projects, 2022
Poliomyelitis - Dormant Projects, 2022 (Contd..1)
Poliomyelitis - Discontinued Products, 2022
List of Figures
Number of Products under Development for Poliomyelitis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
